The compounded-GLP-1 cliff: what the proposed 503B bulks-list exclusion means for you

The FDA's shortage-based permission for bulk compounded semaglutide and tirzepatide ended in 2025, and a May 2026 FDA proposal would keep outsourcing facilities from making them in bulk under a different part of the law. That permission was the legal basis that let telehealth platforms supply hundreds of thousands of patients through 503B outsourcing facilities. None of this came from a single new rule. It happened because five separate pieces of federal law, some nearly a century old, work together to define what "legal" compounded GLP-1 access even means. Understanding those pieces helps explain what is closing and what still remains open for patients.

That standard, set by the Federal Food, Drug, and Cosmetic Act of 1938, requires a drug to go through premarket review before it can carry FDA approval. Compounded medications, by design, sit outside that process. A compounding pharmacy or outsourcing facility does not submit its version of semaglutide or tirzepatide for the same review that Ozempic, Wegovy, or Zepbound underwent. This is not a loophole or an oversight. It is the structural reason compounded GLP-1s were never approved products in the first place, even during the years when they were legal to dispense.

That classification came from the Durham-Humphrey Amendment of 1951, which split drugs into prescription and over-the-counter categories and required a licensed practitioner's involvement for the former. That framework is what makes patient-specific compounding possible at all under section 503A: a pharmacist can only prepare an individualized formulation in response to a valid prescription tied to a real patient's documented need. Without that 1951 line between prescription and non-prescription drugs, there would be no legal foundation for the 503A pathway that remains open even as the 503B bulk route closes. It is a narrower path than bulk compounding, built one prescription at a time, but it rests on law that predates the GLP-1 shortage by more than seventy years.

That deal, created by the Omnibus Budget Reconciliation Act of 1990, set up the Medicaid Drug Rebate Program, in which manufacturers agree to rebate a portion of the price back to Medicaid in exchange for their drugs being covered. That arrangement matters here because it shapes what happens to patients who lose access to compounded versions. Coverage for the FDA-approved products, the ones Medicaid rebate agreements apply to, does not automatically extend to compounded alternatives, since compounded drugs sit outside the approval and rebate structure altogether. For patients relying on Medicaid, the end of compounded access does not open a new coverage door. It shifts the question back to whether the approved product itself is covered and affordable under the existing rebate arrangement.

That law, the Veterans Health Care Act of 1992, created the 340B Drug Pricing Program, which requires manufacturers to sell outpatient drugs at a discount to certain safety-net providers and covered entities. Some patients losing access to compounded GLP-1s may find that a 340B-eligible clinic or health center offers a path to the approved product at a lower price than they would otherwise pay. This is not a universal fix, since 340B pricing depends on where a patient gets care and whether that provider qualifies as a covered entity. Still, for patients facing the closing compounded market, it is one of the few federally established discount mechanisms worth asking about.

That authority, granted under the FDA Safety and Innovation Act of 2012, gave the FDA formal power to track and publish drug shortages. The 2012 law created the shortage list. The right to compound copies of a drug comes from sections 503A and 503B of the food and drug law, added in 1997 and 2013, and those sections give compounders more room while a drug is on that list. That is why compounded semaglutide and tirzepatide spread from 2022. Tirzepatide came off the shortage list in October 2024, confirmed in December 2024, and semaglutide came off in February 2025. The FDA's grace periods for outsourcing facilities ended in March and May 2025, so shortage-era bulk compounding is already over. In a May 1, 2026 Federal Register notice, the FDA proposed not to add semaglutide, tirzepatide or liraglutide to the list of ingredients outsourcing facilities may use in bulk. That is a separate review of clinical need under section 503B, and it does not depend on shortage status. Comments were open until July 30, 2026, and the FDA has not made a final decision.

None of these laws were written with GLP-1 drugs in mind, yet together they explain both why compounded access existed and why it has narrowed. If you currently rely on a compounded semaglutide or tirzepatide product, the practical step is to talk with your prescriber now about what an FDA-approved alternative would look like for you, including whether a 340B-eligible provider or your existing coverage changes that calculation. Waiting until the FDA makes a final decision leaves fewer options and less time to sort out coverage or dosing. This is a legal and supply question, not a medical one, but it is worth planning for now.

By Amanda Bonello